Intravenous Dexamethsone
Osteoarthritis, Hip
Poznan University of Medical SciencesUNKNOWNPhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Osteoarthritis, Hip cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE Poznan University of Medical Sciences | Phase 4 | BBB |
Dexasone Poznan University of Medical Sciences | Phase 4 | BBB |
Celecoxib Pfizer | Phase 4 | BB |
Remimazolam Seoul National University Hospital | Phase 4 | BB |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | BB |
View all 15 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →